• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

专家对在西班牙开展促进获取孤儿药和罕见病特殊护理公平性的举措的看法:德尔菲共识。

The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: A Delphi consensus.

机构信息

Committee for Orphan Medicinal Products (COMP), European Medicines Agency (EMA), London, UK; Autonomous University, Barcelona, Spain.

Outcomes'10, Castellon, Spain.

出版信息

Health Policy. 2018 Jun;122(6):590-598. doi: 10.1016/j.healthpol.2018.03.002. Epub 2018 Mar 15.

DOI:10.1016/j.healthpol.2018.03.002
PMID:29572017
Abstract

OBJECTIVES

To reach a consensus amongst experts on the most feasible actions to be undertaken to facilitate patient access to specialised care and orphan drugs (OD) in the public health sector in Spain.

METHODS

Two Delphi rounds were completed. The questionnaire was based on a literature review and 2 focus groups. Agreement was sought on the desire (D) and prognosis (P) for the implementation within the next 5 years, on a 5-point Likert scale. Consensus was reached when ≥75% participants chose agreement (1-2) or disagreement options (4-5).

RESULTS

82 experts on rare disease (RD) participated. Agreement on the D and P was reached in 66.07% statements: OD pricing review [absence of clinical effectiveness (D:85.37%; P:85.90%), target population increase (D:79.27%; P:91.03%)]; reference team definition of referral protocols and clinical practice guidelines (D: 97.56%; P: 89.74%); and a unified, usable, etiology-based registry (D:97.56%; P:84.62%). D and P assessment diverged in 32.14% items: creation of a specific funding system for OD (D: 97.56%; P: 60.25%); and a network of medical teams to coordinate the care of RD patients (D: 99%; P: 62%).

CONCLUSIONS

The results have shown the need to promote dialogue between stakeholders, introduce European recommendation to national and regional Spanish policies and set up priorities and undertake actions to drive relevant changes in current medical practice in managing RD patients.

摘要

目的

就如何在西班牙公共卫生部门为患者获得专科治疗和罕见病药物(OD)提供便利,在专家中达成最可行的行动共识。

方法

完成了两轮 Delphi 研究。问卷基于文献回顾和 2 个焦点小组。采用 5 分李克特量表,对未来 5 年内实施的意愿(D)和预测(P)进行了评估。当≥75%的参与者选择同意(1-2)或不同意(4-5)选项时,即可达成共识。

结果

共有 82 名罕见病专家参与。在 66.07%的陈述中达成了对 D 和 P 的共识:OD 定价审查[缺乏临床疗效(D:85.37%;P:85.90%)];目标人群增加(D:79.27%;P:91.03%)];参考小组制定转诊协议和临床实践指南(D:97.56%;P:89.74%);以及建立一个统一、可用、基于病因的登记系统(D:97.56%;P:84.62%)。在 32.14%的项目中,D 和 P 的评估存在分歧:为 OD 创建特定的资金系统(D:97.56%;P:60.25%);以及建立一个协调 RD 患者护理的医疗团队网络(D:99%;P:62%)。

结论

结果表明,需要促进利益相关者之间的对话,将欧洲建议引入国家和地区西班牙政策,并确定优先事项并采取行动,推动当前管理 RD 患者医疗实践的相关变革。

相似文献

1
The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: A Delphi consensus.专家对在西班牙开展促进获取孤儿药和罕见病特殊护理公平性的举措的看法:德尔菲共识。
Health Policy. 2018 Jun;122(6):590-598. doi: 10.1016/j.healthpol.2018.03.002. Epub 2018 Mar 15.
2
Consensus on the criteria needed for creating a rare-disease patient registry. A Delphi study.关于创建罕见病患者登记册所需标准的共识。一项德尔菲研究。
J Public Health (Oxf). 2016 Jun;38(2):e178-86. doi: 10.1093/pubmed/fdv099. Epub 2015 Aug 19.
3
Strategic discussion on funding and access to therapies targeting rare diseases in Spain: an expert consensus paper.针对西班牙罕见病治疗方法的资金投入和可及性的战略探讨:专家共识文件。
Orphanet J Rare Dis. 2023 Feb 24;18(1):41. doi: 10.1186/s13023-023-02635-3.
4
Analysing criteria for price and reimbursement of orphan drugs in Spain.西班牙罕见病药物的定价与报销分析标准
Farm Hosp. 2019 Jul 1;43(4):121-127. doi: 10.7399/fh.11147.
5
Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project.采用德尔菲共识法为新诊断的多发性骨髓瘤患者定义一套标准化结局指标:IMPORTA项目
BMJ Open. 2018 Feb 22;8(2):e018850. doi: 10.1136/bmjopen-2017-018850.
6
The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study.印度孤儿药组织的工作、目标、挑战、成就和建议:基于访谈的研究。
Orphanet J Rare Dis. 2019 Nov 4;14(1):241. doi: 10.1186/s13023-019-1224-0.
7
Expert Consensus on the Management of Patients with Postmenopausal Osteoporosis in the Spanish Healthcare System.西班牙医疗体系中绝经后骨质疏松症患者管理的专家共识
Adv Ther. 2016 Apr;33(4):658-69. doi: 10.1007/s12325-016-0314-9. Epub 2016 Mar 17.
8
Multidisciplinary expert consensus on secondary fracture prevention in Spain.西班牙多学科专家共识:预防二次骨折
Arch Osteoporos. 2021 Feb 27;16(1):48. doi: 10.1007/s11657-021-00878-w.
9
Determinants of orphan drugs prices in France: a regression analysis.法国孤儿药价格的决定因素:一项回归分析。
Orphanet J Rare Dis. 2017 Apr 21;12(1):75. doi: 10.1186/s13023-016-0561-5.
10
Orphan drugs for rare diseases: is it time to revisit their special market access status?罕见病孤儿药:是否到了重新审视其特殊市场准入地位的时候?
Drugs. 2012 Jul 30;72(11):1437-43. doi: 10.2165/11635320-000000000-00000.

引用本文的文献

1
A systematic review of moral reasons on orphan drug reimbursement.孤儿药补偿的道德理由系统评价。
Orphanet J Rare Dis. 2021 Jun 30;16(1):292. doi: 10.1186/s13023-021-01925-y.